(19)
(11) EP 1 106 179 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
07.01.2004 Bulletin 2004/02

(43) Date of publication A2:
13.06.2001 Bulletin 2001/24

(21) Application number: 01101953.6

(22) Date of filing: 21.02.1997
(51) International Patent Classification (IPC)7A61K 31/4453, A61K 31/40, A61K 31/4439, A61K 31/4725, A61P 43/00
(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

(30) Priority: 28.02.1996 US 13212 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
97301147.1 / 0792641

(71) Applicant: PFIZER INC.
New York, N.Y. 10017 (US)

(72) Inventors:
  • Maclean, David B.
    Providence, Rhode Island 02906 (US)
  • Thompson, David D.
    Gales Ferry, Connecticut 06335 (US)

(74) Representative: Motion, Keith Robert et al
Pfizer Limited Patents Department Ramsgate Road
Sandwich, Kent CT13 9NJ
Sandwich, Kent CT13 9NJ (GB)

   


(54) Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions


(57) The present invention provides the use of a compound (I) for the manufacture of a medicament for inhibiting pathological conditions related to organ systems which respond to estrogen agonists:- wherein
  • A is CH2 or NR where R is H or C1-C6 alkyl
  • B, D and E are each CH or N,
  • and Y, Z1 and G are certain stated substituents.








Search report